Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) with potent antioxidant properties. It has been investigated in amyotrophic lateral sclerosis (ALS) based on the hypothesis that oxidative stress contributes to motor neuron degeneration. Idebenone is a mitochondria-targeted antioxidant that can bypass the electron transport chain defects and reduce oxidative damage[@mancuso2012].
Amyotrophic lateral sclerosis is characterized by progressive loss of upper and lower motor neurons. Oxidative stress is one of the established pathological mechanisms in ALS, with evidence of increased oxidative damage to proteins, lipids, and DNA in patient tissues and animal models. This makes antioxidant therapy an attractive therapeutic approach.
Trial Details
Phase: Phase 2/3
Status: Completed
Drug: Idebenone (Catena®, Sovrima®)
Dosage: 500-2700 mg daily (divided doses)
Patient Population: Adults with definite or probable ALS (El Escorial criteria)
Duration: 12-18 months
ClinicalTrials.gov Identifier: NCT00328861
Enrollment: 400+ patients across multiple sites
Background and Rationale
Oxidative Stress in ALS
Multiple lines of evidence support the role of oxidative stress in ALS pathogenesis:
...
Overview
Idebenone is a synthetic analog of coenzyme Q10 (CoQ10) with potent antioxidant properties. It has been investigated in amyotrophic lateral sclerosis (ALS) based on the hypothesis that oxidative stress contributes to motor neuron degeneration. Idebenone is a mitochondria-targeted antioxidant that can bypass the electron transport chain defects and reduce oxidative damage[@mancuso2012].
Amyotrophic lateral sclerosis is characterized by progressive loss of upper and lower motor neurons. Oxidative stress is one of the established pathological mechanisms in ALS, with evidence of increased oxidative damage to proteins, lipids, and DNA in patient tissues and animal models. This makes antioxidant therapy an attractive therapeutic approach.
Trial Details
Phase: Phase 2/3
Status: Completed
Drug: Idebenone (Catena®, Sovrima®)
Dosage: 500-2700 mg daily (divided doses)
Patient Population: Adults with definite or probable ALS (El Escorial criteria)
Duration: 12-18 months
ClinicalTrials.gov Identifier: NCT00328861
Enrollment: 400+ patients across multiple sites
Background and Rationale
Oxidative Stress in ALS
Multiple lines of evidence support the role of oxidative stress in ALS pathogenesis:
Elevated Biomarkers: Increased 8-OHdG (DNA damage), 4-HNE (lipid peroxidation), and protein carbonyls in ALS patients
Genetic Links: SOD1 mutations cause oxidative stress in familial ALS
Mitochondrial Dysfunction: Complex I and IV deficiency in ALS spinal cord
Free Radical Production: Activated microglia produce excessive ROS
CoQ10 and Idebenone
Coenzyme Q10 is a natural component of the mitochondrial electron transport chain. Idebenone was developed as a synthetic analogue with enhanced bioavailability and antioxidant properties:
Lipophilicity: Better brain penetration than CoQ10
Electron Shuttling: Can bypass defective Complex I
Antioxidant Activity: Direct free radical scavenging
No Pro-oxidant Effect: Unlike high-dose CoQ10, doesn't become pro-oxidant
Mechanism of Action
Idebenone acts as a mitochondrial antioxidant through multiple pathways:
Antioxidant Effects
Free Radical Scavenging: Neutralizes reactive oxygen species (ROS) including superoxide, peroxyl, and peroxynitrite[@gerom2018]
Lipid Peroxidation Prevention: Protects cell membranes from oxidative damage
Mitochondrial DNA Protection: Protects mtDNA from oxidative lesions
Synaptic Antioxidant: Protects synaptic terminals from oxidative damage
Mitochondrial Function
Electron Flow Bypass: Can accept electrons from Complex I and II, bypassing defects
ATP Production Support: Helps maintain cellular energy production
CoQ10 Analogue: Functions as CoQ10 substitute in electron transport